Phase 3 Trials

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Topline phase 1/2 results suggest the MTAP‑deleted, RAS‑mutant combination could enable a precision, chemotherapy‑sparing first‑line approach if randomized trials confirm the finding.